Cardiology
Conference Coverage
Music’s charms may soothe heart failure’s effects
Evidence builds that music, either heard or sung, exerts measurable benefits for heart failure and other cardiovascular diseases.
Conference Coverage
Dapagliflozin’s CKD performance sends heart failure messages
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians...
News
AHA scientific statement highlights cardiorenal benefit of new diabetes drugs
SGLT2 inhibitors and GLP-1 receptor agonists should be considered in people with type 2 diabetes and chronic kidney disease to protect against...
News
New data challenge primary care’s inattention to aldosterone in hypertension
Conference Coverage
Higher glycemic time in range may benefit T2D patients
A post hoc analysis linked greater blood-glucose time in range with fewer hypoglycemic, microvascular, and major adverse cardiac events in T2D...
Conference Coverage
Exercise cuts diabetes death risk by a third in two studies
Results of two new studies provide further evidence that exercise reduces all-cause and cardiovascular mortality in those with type 2 diabetes.
Conference Coverage
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25....
Conference Coverage
VERTIS CV: Ertugliflozin’s proven benefits fall short of other SGLT2 inhibitors
Added analyses from ertugliflozin’s cardiovascular outcome trial hint at SGLT2 inhibitor–consistent benefits, but proven benefits remain scant.
News
Pesco-Mediterranean diet, fasting ‘ideal’ to reduce CVD risk
Adhering to the Mediterranean diet and limiting eating time can lower the risk for cardiovascular disease.
News
Observational study again suggests lasting impact of COVID-19 on heart